Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor used as add-on therapy in severe COPD with frequent exacerbations. Its anti-inflammatory mechanism involves:

• A Inhibition of PDE4 prevents breakdown of intracellular cAMP in inflammatory cells (neutrophils, macrophages, eosinophils, dendritic cells), elevated cAMP activates PKA which suppresses inflammatory cytokine synthesis, NF-kB activation, and neutrophil migration ✓
• B Direct antagonism of IL-17 receptor on bronchial epithelium reducing mucus hypersecretion
• C Inhibition of leukotriene synthesis via 5-lipoxygenase blockade in bronchial mucosa
• D Selective beta-2 adrenoceptor agonism combined with anti-inflammatory activity in airway smooth muscle

Explanation

PDE4 is the predominant phosphodiesterase in immune-inflammatory cells. Its inhibition by roflumilast blocks cAMP hydrolysis, elevating intracellular cAMP. In neutrophils, macrophages, and lymphocytes, elevated cAMP activates protein kinase A (PKA), which phosphorylates and inhibits key inflammatory transcription factors including NF-kB, reduces TNF-alpha and IL-8 production, and diminishes neutrophil chemotaxis and adhesion. Roflumilast does not have direct bronchodilator activity but is specifically approved for COPD patients with chronic bronchitis and frequent exacerbations despite optimal bronchodilator therapy.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.